Trends - Eli Lilly and Co - Business Recorder

Eli Lilly and Co

Lilly raises 2021 outlook on higher COVID-19 drugs sales

Eli Lilly and Co raised its full-year profit and revenue forecasts on Tuesday, citing expected higher sales of its...

Published 26 Oct, 2021 05:01pm

Business & Finance

Lilly to seek accelerated FDA approval for Alzheimer's drug this year

The FDA granted donanemab a breakthrough therapy designation, meant to expedite the development and review of medicines for serious or life-threatening conditions.

Published 24 Jun, 2021 04:36pm

Business & Finance

Lilly hit by staff accusations, FDA scrutiny at COVID drug factories

The source, who spoke on condition of anonymity, said the findings involved the production of drugs including Lilly's COVID-19 therapy, whose use in the United States is funded by the federal government.
Separately, FDA inspectors in March identified numerous manufacturing lapses at a second Lilly facility in Indianapolis that bottles the COVID-19 therapy and other drugs.

Published 05 May, 2021 06:50pm

Business & Finance

Eli Lilly to supply 400,000 tablets of its COVID-19 treatment to India

With 3.45 million active cases, India recorded 357,229 new infections over the last 24 hours, while deaths rose 3,449 for a toll of 222,408, health ministry data showed. Experts say actual numbers could be five to 10 times higher, however.
The drugmaker said it will work urgently to increase the supply multifold over the coming weeks.

Published 04 May, 2021 06:13pm

Business & Finance

Eli Lilly profit forecast trimmed as vaccines dent US demand for COVID-19 drugs

Nearly 30% of the US population has been vaccinated against COVID-19, hitting demand for antibody drugs that already suffered from slower-than-expected uptake by hospitals.
Sales of other high-profile Lilly drugs also fell short of Wall Street expectations and its shares fell 3% to $181.64 in morning trading.

Published 27 Apr, 2021 08:23pm

Business & Finance

Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab

The request made to the US Food and Drug Administration is not due to any new safety issues, but in response to the new variants in the country that could be resistant to bamlanivimab when used alone, the drugmaker said in a statement.
Hospitals with bamlanivimab supply should now order etesevimab to pair with it, Lilly said.

Published 16 Apr, 2021 05:45pm

Business & Finance

Eli Lilly to focus on selling COVID-19 antibody drug combination

Lilly and the US government have agreed to modify their existing agreement to enable the supply of etesevimab to complement doses of bamlanivimab the US government had already purchased, the drugmaker said.
The earlier supply agreement for bamlanivimab has been terminated and cancels the remaining 350,856 doses of bamlanivimab that were scheduled to be delivered by the end of March 2021.

Published 12 Apr, 2021 09:15pm

Business & Finance

Lilly Alzheimer's drug shows benefit on cognition, function in mid-stage trial

The drug, donanemab, also showed positive trends that failed to reach statistical significance on a range of secondary trial goals, the company said, providing details for the first time.
The ability to carry out activities like dressing and eating is often impacted by Alzheimer's disease, which reduces cognitive ability like memory and language.

Updated 13 Mar, 2021 09:08pm

Business & Finance

Eli Lilly's combo therapy for COVID-19 cuts serious illness and death in large study

The previous study, which published data in January, used a higher dose of the drugs and reduced risk of hospitalization by 70%.
"I expect this data to continue to drive more utilization" of the antibodies," said Daniel Skovronsky, chief scientific officer at Eli Lilly.

Published 10 Mar, 2021 06:32pm

Business & Finance

US to buy at least 100,000 doses of Lilly's COVID-19 antibody therapy

The US government will have the option to purchase up to an additional 1.1 million doses through Nov. 25, the company said.
United States had already agreed to buy 1.45 million doses of bamlanivimab alone, Lilly said.

Published 26 Feb, 2021 06:33pm

Business & Finance

Eli Lilly in deal with Rigel to develop autoimmune therapy for up to $960mn

Rigel will receive an upfront cash payment of $125 million, with the potential for an additional up to $835 million in milestone payments.
Lilly will also lead all clinical development and commercialization of the treatment in central nervous system diseases.

Published 18 Feb, 2021 06:52pm

Business & Finance

Lilly says CFO resigns after investigation into inappropriate relationship

The drugmaker said it immediately hired external counsel to conduct an independent probe after it was made aware of the allegations.
Lilly said the behavior exhibited poor judgment by Smiley. The company would not give further details on the communications or the number of employees involved.

Updated 09 Feb, 2021 11:32pm

Business & Finance

Eli Lilly profit rises 41.5pc as COVID-19 drug lifts sales

The company reported worldwide revenue of $871.2 million in the fourth quarter from the therapy, bamlanivimab.
Net earnings rose to $2.12 billion, or $2.32 per share, in the fourth quarter ended Dec. 31 from $1.50 billion, or $1.64 per share, a year earlier.

Published 29 Jan, 2021 06:00pm

Business & Finance

Lilly antibody combo therapy cuts risk of COVID-19 deaths

Lilly said the study has met both the main goal of reducing risk of death and hospitalization and all key secondary goals.
The ongoing trial will enroll up to 3,300 participants across all treatment groups, Lilly said.

Published 26 Jan, 2021 08:02pm

Markets

Wall St retreats from all-time highs after strong run; Twitter slumps

Twitter slumps after Trump's account suspension.
Boeing falls after 737-500 jet crash.
Eli Lilly jumps on upbeat data from an Alzheimer's drug trial.
Indexes down: Dow 0.54%, S&P 0.75%, Nasdaq 1.22%.

Published 11 Jan, 2021 09:04pm

Markets

Wall St set to slip from all-time highs after strong run; Twitter slumps

Twitter slumps after Trump's account suspension.
Boeing falls after 737-500 jet crash.
Eli Lilly jumps on upbeat data from an Alzheimer's drug trial.
Futures down: Dow 0.91%, S&P 0.84%, Nasdaq 0.88%.

Published 11 Jan, 2021 07:46pm

Business & Finance

Lilly says Alzheimer's drug slows clinical decline in mid-stage trial

The drug is an antibody designed to remove clumps of the Alzheimer's-related protein beta amyloid from the brain.
Lilly said the mid-stage trial of 272 patients met its main goal of showing a statistically significant change in clinical decline over 18 months.

Published 11 Jan, 2021 06:51pm

Business & Finance

Eli Lilly to supply 26,000 doses of COVID-19 antibody drug to Canada

The treatment, bamlanivimab, which was developed in partnership with Canadian biotech company AbCellera,
The drugmaker said additional doses will be supplied to Canada on a monthly basis.

Published 25 Nov, 2020 12:18am

Business & Finance

Lilly misses estimates on weak demand, COVID drug development costs

The company did not provide any fresh update on the treatment in its results statement.
Lilly said it expects 2020 COVID-19 research and development expense to be roughly $400 million, sending its shares down 4% before the opening bell.

Published 27 Oct, 2020 04:56pm

Business & Finance

Lilly's rheumatoid arthritis drug cuts COVID-19 deaths in trial

Lilly said the effect was most pronounced in patients on oxygen therapy, according to data from a US government-backed trial.
Lilly said 5.1% of patients on the drug combination died after 29 days versus 7.8% patients given remdesivir,

Published 09 Oct, 2020 12:49am

Business & Finance

Eli Lilly applies for emergency use of antibody drug for COVID-19

The drugmaker said its two-antibody cocktail helped reduce viral levels more than the single antibody treatment had in a prior study.
We believe that Lilly's data provides some real evidence that the combo mAb (monoclonal antibody) approach may provide meaningful clinical benefits.

Published 08 Oct, 2020 12:28am

Business & Finance

Lilly, Amgen partner to manufacture potential COVID-19 drugs

Antibody treatments work by recognizing and locking onto foreign invaders to prevent infection of healthy cells.
We are impressed with Lilly's data, in particular the reduction in hospitalizations, and are enthusiastic about the potential for these neutralizing antibodies as a therapeutic for COVID-19.

Published 17 Sep, 2020 06:23pm

Business & Finance

Eli Lilly's rheumatoid arthritis drug helps recovery in COVID-19 patients

Lilly said the drug, which is branded as Olumiant, in combination remdesivir showed a roughly one-day reduction.
Remdesivir is at the forefront of the fight against COVID-19 after the drug was granted an EUA in May.

Published 14 Sep, 2020 04:51pm

Forex
World
Commodity

Currency	Rate
USD PKR Interbank Selling / Jan 17	278.75
USD PKR Interbank Buying / Jan 17	278.65
USD to Japanese Yen / Jan 17	156.30
USD to Swiss Franc / Jan 17	0.92
Pound Sterling to USD / Jan 17	1.22
Euro to USD / Jan 17	1.03

Stock	Volume
S&P 500 / Jan 17	5,996.66
India Sensex / Jan 17	76,619.33
Tokyo Nikkei / Jan 17	38,451.46
Nasdaq / Jan 17	19,630.20
Hang Seng / Jan 17	19,584.06
FTSE 100 / Jan 17	8,505.22
Dow Jones / Jan 17	43,487.83
Germany DAX 30 / Jan 17	20,903.39

Item	Value
Crude Oil USD/Barrel / Jan 17	78.88
Karachi Cotton PKR/37.32 KG / Jan 17	18,785
Gold 10 Grams PKR / Jan 17	242,283
Gold Spot USD/Ounce / Jan 17	2,703.25
Cotton US¢/pound / Jan 17	67.60
Petrol/Litre / Jan 19	256.13

Gainers
Losers
Leaders

Stock	Price
Burj Clean Energy Modaraba / Jan 17 Burj Clean Energy Modaraba(GEM)(GEMBCEM)	7.60 ▲ 1.00 (15.15%)
S.G.Power / Jan 17 S.G. Power Limited(SGPL)	9.51 ▲ 1.00 (11.75%)
Jahangir Sidd(Pref) / Jan 17 Jahangir Sidd(Pref)(JSCLPSA)	10.50 ▲ 1.00 (10.53%)
AN Textile Mill / Jan 17 AN Textile Mills Limited(ANTM)	12.82 ▲ 1.17 (10.04%)
Jah.Sidd. Co. / Jan 17 Jahangir Siddiqui & Co. Ltd.(JSCL)	23.62 ▲ 2.15 (10.01%)
Agritech Non-voting / Jan 17 Agritech Non-Voting Preference(AGLNCPS)	24.20 ▲ 2.20 (10.00%)
Arif Habib Ltd. / Jan 17 Arif Habib Limited(AHL)	66.21 ▲ 6.02 (10.00%)
Bilal Fibres / Jan 17 Bilal Fibres Limited(BILF)	15.95 ▲ 1.45 (10.00%)
Citi Pharma Ltd / Jan 17 Citi Pharma Ltd.(CPHL)	77.09 ▲ 7.01 (10.00%)

Stock	Price
JS Global Banking / Jan 17 JS Global Banking Sector (ETF)(JSGBETF)	19.77 ▼ -2.75 (-12.21%)
First Capital Equities / Jan 17 First Capital Equities Limited(FCEL)	5.35 ▼ -0.72 (-11.86%)
Tariq Corp.Pref. / Jan 17 Tariq Corporation Limited-Preference Shares(TCORPCPS)	7 ▼ -0.88 (-11.17%)
Service Textile / Jan 17 Service Industries Textiles Limited(SERT)	14.98 ▼ -1.66 (-9.98%)
Gulshan Sp. / Jan 17 Gulshan Spinning Mills Limited(GSPM)	4.01 ▼ -0.43 (-9.68%)
Zahid Jee Textile / Jan 17 Zahidjee Textile Mills Limited(ZAHID)	27.51 ▼ -2.70 (-8.94%)
Mandviwala / Jan 17 Mandviwala Mauser Plastic Industries(MWMP)	21.50 ▼ -2.00 (-8.51%)
Universal Ins. / Jan 17 The Universal Insurance Company Limited(UVIC)	9.23 ▼ -0.65 (-6.58%)
Tata Textile / Jan 17 Tata Textile Mills Limited(TATM)	47.10 ▼ -2.80 (-5.61%)

Stock	Volume
WorldCall Telecom / Jan 17 Worldcall Telecom Limited(WTL)	103,704,415 ▲ 0.01
Cnergyico PK / Jan 17 Cnergyico PK Limited(CNERGY)	37,108,232 ▲ 0.04
Hub Power Co. / Jan 17 The Hub Power Company Limited(HUBC)	36,743,585 ▲ 5.79
Hascol Petrol / Jan 17 Hascol Petroleum Limited(HASCOL)	32,265,861 ▲ 0.83
Dewan Motors / Jan 17 Dewan Farooque Motors Limited(DFML)	28,402,498 ▲ 2.84
Citi Pharma Ltd / Jan 17 Citi Pharma Ltd.(CPHL)	24,195,904 ▲ 7.01
Pak Refinery / Jan 17 Pakistan Refinery Limited(PRL)	17,625,081 ▲ 0.94
Fauji Foods Ltd / Jan 17 Fauji Foods Limited(FFL)	16,675,539 ▲ 0.30
K-Electric Ltd. / Jan 17 K-Electric Limited(KEL)	16,024,776 ▲ 0.09

Markets →

Budget 2024-25: income tax calculator for FY25

Eli Lilly and Co

Most Popular